Last reviewed · How we verify
NCT07198659: NeuMed-uPC
A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer
EARLY_PHASE1 trial testing Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents in Unresectable Pancreatic Cancer in 3 participants. Currently enrolling.
14 July 2027
Quick facts
| Lead sponsor | The First Affiliated Hospital of Air Force Medicial University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 14 July 2025 |
| Primary completion | 14 July 2027 |
| Estimated completion | 14 July 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Monomethyl Auristatin E (MMAE) / autologous neutrophil biological agents
Conditions studied
- Unresectable Pancreatic Cancer — all drugs for Unresectable Pancreatic Cancer →
Sponsor
The First Affiliated Hospital of Air Force Medicial University
Who can join
Adults 18 to 70, any sex, with Unresectable Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if Autologous Drug-Loaded Neutrophils (NeuMed) can treat patients with Unresectable Pancreatic Cancer. The drug carried by the Autologous Neutrophils is Monomethyl Auristatin E. The main questions it aims to answer are: First, to verify the safety of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer. Second, to assess the anti-tumor efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in patients with Unresectable Pancreatic Cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07198659
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Unresectable Pancreatic Cancer
Currently open trials in the same condition.
- NCT06135896 — Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers · Phase 2 · recruiting
- NCT05601323 — A Study of Suizenji in Patients With Unresectable Pancreatic Cancer · NA · active not recruiting
- NCT04789486 — Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT03138720 — Pre-operative Treatment for Patients With Untreated Pancreatic Cancer · Phase 2 · active not recruiting
- NCT02495896 — Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastati · Phase 1 · active not recruiting
Other The First Affiliated Hospital of Air Force Medicial University trials
Trials by the same sponsor.
- NCT07240987 — Mesenchymal Stem Cells for Chronic Kidney Diseases · Phase 1, PHASE2 · not yet recruiting
- NCT07266181 — Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropat · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07198659 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Air Force Medicial University
- Last refreshed: 30 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07198659.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing